We are live on ! Find out more
NVRO

NEVRO CORP.

Delisted

NVRO was delisted on the 2nd of April, 2025.

176 hedge funds and large institutions have $1.63B invested in NEVRO CORP. in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 56 increasing their positions, 60 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $1.53B → $1.63B (+$107M)

4% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 28

1% more funds holding

Funds holding: 175176 (+1)

7% less repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 60

11% less call options, than puts

Call options by funds: $29.1M | Put options by funds: $32.7M

Holders
176
Holders Change
+1
Holders Change %
+0.57%
% of All Funds
3.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
29
Increased
56
Reduced
60
Closed
28
Calls
$29.1M
Puts
$32.7M
Net Calls
-$3.64M
Net Calls Change
-$3.18M

NVRO Hedge Fund Activity: Q3 2022 in Review

176 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q3 2022, worth a combined $1.63B — up 7% from $1.53B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new NVRO positions and 28 closed out — a net gain of 1 holder — while 56 added to existing stakes and 60 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $150M. The largest seller was T. Rowe Price Associates, cutting an estimated $33.8M.

  • 176 institutional investors held NEVRO CORP. (NVRO) as of Q3 2022, up from 175 in Q2 2022.
  • Funds reported $1.63B of NEVRO CORP. stock for Q3 2022, up 7% quarter-over-quarter.
  • 29 funds opened new NEVRO CORP. positions in Q3 2022 and 28 closed out, a net change of +1 holder.
  • The largest NEVRO CORP. buyer in Q3 2022 was Fidelity Investments, an estimated $150M added.
  • The largest NEVRO CORP. seller in Q3 2022 was T. Rowe Price Associates, an estimated $33.8M sold.

Based on aggregated 13F filings for Q3 2022.